Positive clinically meaningful efficacy signs in the inhaled AAT group including an approximate 50% reduction in severe exacerbation rates versus placebo Continues with plans to …
Kamada Announces Significantly Improved Infusion Rate for Glassia
Lowers time from preparation to finish for patients with Alpha-1 Antitrypsin Deficiency by more than 75% April 24, 2014 Kamada Ltd., a plasma-derived protein therapeutics company …
Kamada Announces U.S. Proof-of-Concept Study with Glassia for Graft-Versus-Host Disease
April 3, 2014 Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announced today a U.S.-based proof-of-concept (POC) study with Glassia® to treat graft-versus-host …
Kamada Announces Initiation of a Phase 2 U.S. Clinical Trial of Inhaled AAT to Treat Alpha-1 Antitrypsin Deficiency
March 24, 2014 Kamada Ltd., a plasma-derived protein therapeutics company focused on orphan indications, announces the initiation of a new Phase 2 U.S. clinical trial of …
Kamada Completes Enrollment in U.S. Clinical Trial for Post-Exposure Treatment for Rabies
March 4, 2014 Kamada Ltd., a plasma-derived protein therapeutics company, focused on orphan indications, announces that it has completed enrollment in its U.S. Phase 2/3 clinical …